| Literature DB >> 32949574 |
Gerlando Natalello1, Giacomo De Luca2, Laura Gigante3, Corrado Campochiaro2, Enrico De Lorenzis4, Lucrezia Verardi3, Annamaria Paglionico3, Luca Petricca3, Anna Maria Martone5, Stefania Calvisi6, Marco Ripa7, Giulio Cavalli2, Emanuel Della-Torre2, Moreno Tresoldi6, Francesco Landi5, Silvia Laura Bosello3, Elisa Gremese3, Lorenzo Dagna2.
Abstract
OBJECTIVE: Increasing evidence points to endothelial dysfunction as a key pathophysiological factor in coronavirus disease-2019 (COVID-19). No specific methods have been identified to predict, detect and quantify the microvascular alterations during COVID-19. Our aim was to assess microvasculature through nailfold videocapillaroscopy (NVC) in COVID-19 patients.Entities:
Keywords: COVID-19; Micro-thrombosis; Microangiopathy; Nailfold videocapillaroscopy
Year: 2020 PMID: 32949574 PMCID: PMC7494493 DOI: 10.1016/j.mvr.2020.104071
Source DB: PubMed Journal: Microvasc Res ISSN: 0026-2862 Impact factor: 3.514
Population characteristics.
| All patients | Acute | Recovered | ||
|---|---|---|---|---|
| Age, years, mean ± SD | 58.8 ± 13.2 | 62.5 ± 13.6 | 57.3 ± 12.8 | .068 |
| Male, n (%) | 56 (68.3) | 20 (71.4) | 36 (66.7) | .8 |
| Duration from onset, days, mean ± SD | 37.3 ± 23.1 | 7.2 ± 5.0 | 52.2 ± 7.1 | |
| Duration from discharge, days, mean ± SD | NA | NA | 31.6 ± 9.3 | NA |
| Smoke (current), n (%) | 11 (13.4) | 7 (25.0) | 4 (7.4) | |
| Hypertension, n (%) | 25 (30.5) | 10 (35.7) | 15 (27.8) | .48 |
| Diabetes, n (%) | 9 (11.0) | 7 (25.0) | 2 (3.7) | |
| Rheumatic disease | 4 (4.9) | 3 (10.7) | 1 (1.8) | .11 |
| BMI >25 kg/m2, n (%) | 50 (61.0) | 16 (57.1) | 34 (63.0) | .92 |
| Acral symptoms | 8 (9.8) | 0 (0) | 8 (14.8) | |
| Oxygen therapy | 47 (57.3) | 17 (60.7) | 30 (55.6) | .81 |
| ICU, n (%) | 5 (6.1) | 0 (0) | 5 (9.3) | .16 |
| Anti-IL6R, n (%) | 21 (25.6) | 7 (25.0) | 14 (25.9) | .93 |
| Enoxaparin | 39 (47.5) | 24 (85.7) | 15 (25.9) | |
| PTE or DVT, n (%) | 8 (9.8) | 5 (17.9) | 3 (5.6) | .15 |
SD: standard deviation; BMI: body mass index; ICU: intensive care unit; IL6R: interleukin-6 receptor; PTE: pulmonary thrombo-embolism; DVT: deep vein thrombosis.
Bold is used to highlight a p-value <0.05 which is therefore considered statistically significant.
P comparisons between acute and recovered patients.
Temporally related to COVID-19.
During hospitalization.
Prevalence of elementary capillaroscopic abnormalities (frequency score 2–3) and comparisons in acute vs recovered vs patients (Fisher's exact).
| Abnormality | Frequency score 2–3 | |||
|---|---|---|---|---|
| All patients | Acute | Recovered n = (54) | ||
| Enlarged capillary, n (%) | 50 (61.0) | 4 (14.3) | 46 (85.2) | |
| Giant capillary, n (%) | 0 (0) | 0 (0) | 0 (0) | – |
| Hemosiderin deposit, n (%) | 19 (23.2) | 13 (46.4) | 6 (11.1) | |
| Micro-thrombosis, n (%) | 6 (7.3) | 5 (17.9) | 1 (1.9) | |
| Micro-hemorrhage, n (%) | 13 (15.9) | 8 (28.6) | 5 (9.3) | |
| Capillary density <9/mm, n (%) | 41 (50.0) | 7 (25.0) | 34 (63.0) | |
| Microvascular derangement, n (%) | 39 (47.6) | 14 (50.0) | 25 (46.3) | .8 |
| Capillary ramification, n (%) | 21 (25.6) | 8 (28.6) | 13 (24.1) | .8 |
| Meandering capillary, n (%) | 44 (53.7) | 0 (0) | 44 (81.4) | |
| Sludge flow, n (%) | 44 (53.7) | 22 (78.6) | 22 (40.7) | |
| Pericapillary edema, n (%) | 66 (80.5) | 28 (100) | 38 (70.4) | |
| Subpapillary plexus visibility, n (%) | 7 (8.5) | 1 (3.6) | 6 (11.1) | .4 |
| Empty dermal papilla, n (%) | 12 (14.6) | 0 (0) | 12 (22.2) | |
| Avascular area, n (%) | 3 (3.7) | 0 (0) | 3 (5.6) | .05 |
| Neoangiogenesis, n (%) | 6 (7.3) | 0 (0) | 6 (11.1) | .09 |
Bold is used to highlight a p-value <0.05 which is therefore considered statistically significant.
P comparisons between acute and recovered patients.
Fig. 1Nailfold capillaroscopy abnormalities found in COVID-19 patients (200× magnification). A) Meandering capillaries and microvascular derangement; B) pericapillary edema; C) low capillary density; D) capillary ectasia; E) micro-thrombosis; F) micro-hemorrhage.